Contrast-enhanced ultrasound enhancement features of clear cell renal cell carcinoma using Sonazoid or SonoVue as ultrasound contrast agents and comparative study with contrast-enhanced CT
Contrast-enhanced ultrasound enhancement features of clear cell renal cell carcinoma using Sonazoid or SonoVue as ultrasound contrast agents and comparative study with contrast-enhanced CT[J]. Journal of Clinical Ultrasound in Medicine, 2023,25(11).
Contrast-enhanced ultrasound enhancement features of clear cell renal cell carcinoma using Sonazoid or SonoVue as ultrasound contrast agents and comparative study with contrast-enhanced CT[J]. Journal of Clinical Ultrasound in Medicine, 2023,25(11).DOI:
[Abstract] Objective:To compare the enhancement features of Sonazoid and SonoVue CEUS (contrast-enhanced ultrasound
CEUS) in renal clear cell carcinoma
and compare them with CECT (contrast-enhanced computed tomography
CECT)
to explore the application value of different ultrasound contrast agents and examination methods in the diagnosis of renal clear cell carcinoma. Methods: 47 patients with renal clear cell carcinoma (47 lesions in total) who were diagnosed pathologically in our hospital from June 2020 to September 2022 were selected as the study subjects. All patients underwent CEUS and CECT examinations. According to the different types of ultrasound contrast agents selected
the patients were divided into SonoVue group (21 cases) and Sonazoid group (26 cases). Observe the enhancement characteristics of the lesions in the two groups and compare them with CECT.Results:1. Sonazoid-CEUS and SonoVue-CEUS showed no significant difference in the enhancement mode
peak intensity
and enhancement uniformity of renal clear cell carcinoma between the two groups (P>0.05).2. Comparison of CEUS and CECT enhancement features: The peak intensity of CEUS and CECT in 47 cases of renal clear cell carcinoma was mainly rich in blood supply
which was (42/47
89.36%) and (40/47
85.11%)
respectively
with no significant difference (P>0.05); In CEUS
the proportion of homogeneous diffuse enhancement at the peak of the lesions was significantly higher than that in CECT
which was (12/47
25.53%) and (4/47
8.51%) respectively
and the difference was statistically significant (P<0.05); CEUS showed that the enhancement mode of focus was fast forward in 35 cases (35/47) and fast backward in 42 cases (42/47). Compared with the results of CECT
there was no significant difference between the two (P>0.05). Conclusion; Sonazoid is equally suitable for contrast-enhanced ultrasound of kidney. Like SonoVue-CEUS and CECT
it can well reflect the blood perfusion characteristics of renal clear cell carcinoma
and they can complement each other to provide more valuable information for the diagnosis of renal clear cell carcinoma.